Skip to main content
Erschienen in: Digestive Diseases and Sciences 9/2022

19.11.2021 | Original Article

Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population

verfasst von: Mimi C. Tan, Quynh Ho, Theresa H. Nguyen, Yan Liu, Hashem B. El-Serag, Aaron P. Thrift

Erschienen in: Digestive Diseases and Sciences | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Background/Aims

Screening for gastric intestinal metaplasia (GIM) may lead to early gastric cancer detection. We developed and validated a pre-endoscopy risk prediction model for detection of GIM based on patient-level risk factors in a U.S. population.

Methods

We used data from 423 GIM cases and 1796 controls from a cross-sectional study among primary care and endoscopy clinic patients at the Houston VA. We developed the model using backwards stepwise regression and assessed discrimination using area under the receiver operating characteristic (AUROC). The model was internally validated using cross-validation and bootstrapping. The final expanded model was compared to a model including H. pylori infection alone and a baseline model including remaining terms without H. pylori.

Results

Male sex, older age, non-white race/ethnicity, smoking status, and H. pylori were associated with GIM risk. The expanded model including these terms had AUROC 0.73 (95%CI 0.71–0.76) for predicting GIM and AUROC 0.82 (95%CI 0.79–0.86) for extensive GIM. This model discriminated better than a model including only H. pylori (AUROC 0.66; 95%CI 0.63–0.68) and the baseline model (AUROC 0.67; 95%CI 0.64–0.70). The expanded model performed similarly among primary care (AUROC 0.75) and endoscopy (AUROC 0.73) patients. The expanded model showed sufficient internal validity (cross-validation AUROC 0.72) with little evidence of over-fitting.

Conclusions

We develop and validate a non-invasive risk model for GIM detection in a U.S. population that included terms for sex, age, race/ethnicity, smoking status, and H. pylori infection. Validated risk models would identify individuals with GIM who should be referred for endoscopic screening.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.CrossRef
2.
Zurück zum Zitat Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol 2020;18:534–542.CrossRef Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol 2020;18:534–542.CrossRef
3.
Zurück zum Zitat Wang Z, Graham DY, Khan A, Balakrishnan M, Abrams HR, El-Serag HB, Thrift AP. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol 2018;47:966–975.CrossRef Wang Z, Graham DY, Khan A, Balakrishnan M, Abrams HR, El-Serag HB, Thrift AP. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol 2018;47:966–975.CrossRef
5.
Zurück zum Zitat Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975;2:58–60.CrossRef Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975;2:58–60.CrossRef
6.
Zurück zum Zitat Asaka M, Kato M, Kudo M, Katagiri M, Nishikawa K, Koshiyama H, Takeda H, Yoshida J, Graham DY. Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than aging: studies in asymptomatic Japanese adults. Helicobacter 1996;1:52–56.CrossRef Asaka M, Kato M, Kudo M, Katagiri M, Nishikawa K, Koshiyama H, Takeda H, Yoshida J, Graham DY. Atrophic changes of gastric mucosa are caused by Helicobacter pylori infection rather than aging: studies in asymptomatic Japanese adults. Helicobacter 1996;1:52–56.CrossRef
7.
Zurück zum Zitat Kim GH, Liang PS, Bang SJ, Hwang JH. Screening and surveillance for gastric cancer in the United States: Is it needed? Gastrointest Endosc 2016;84:18–28.CrossRef Kim GH, Liang PS, Bang SJ, Hwang JH. Screening and surveillance for gastric cancer in the United States: Is it needed? Gastrointest Endosc 2016;84:18–28.CrossRef
8.
Zurück zum Zitat Saumoy M, Schneider Y, Shen N, Kahaleh M, Sharaiha RZ, Shah SC. Cost effectiveness of gastric cancer screening according to race and ethnicity. Gastroenterology 2018;155:648–660.CrossRef Saumoy M, Schneider Y, Shen N, Kahaleh M, Sharaiha RZ, Shah SC. Cost effectiveness of gastric cancer screening according to race and ethnicity. Gastroenterology 2018;155:648–660.CrossRef
10.
Zurück zum Zitat Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control 2008;19:227–256.CrossRef Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control 2008;19:227–256.CrossRef
11.
Zurück zum Zitat IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer (IARC Working Group Reports, No. 8). Lyon, 2014. IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer (IARC Working Group Reports, No. 8). Lyon, 2014.
12.
Zurück zum Zitat Tan MC, Mallepally N, Liu Y, El-Serag HB, Thrift AP. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol 2020;115:381–387.CrossRef Tan MC, Mallepally N, Liu Y, El-Serag HB, Thrift AP. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol 2020;115:381–387.CrossRef
13.
Zurück zum Zitat Woo Y, Behrendt CE, Trapp G, Hyun JG, Gonda T, Fong Y, Wang T. Screening endoscopy finds high prevalence of Helicobacter pylori and intestinal metaplasia in Korean American with limited access to health care. J Surg Oncol 2017;116:172–176.CrossRef Woo Y, Behrendt CE, Trapp G, Hyun JG, Gonda T, Fong Y, Wang T. Screening endoscopy finds high prevalence of Helicobacter pylori and intestinal metaplasia in Korean American with limited access to health care. J Surg Oncol 2017;116:172–176.CrossRef
14.
Zurück zum Zitat Da B, Jani N, Gupta N, Jayaram P, Kankotia R, Yao YuC, Dinis-Ribeiro M, Buxbaum J. High-risk symptoms do not predict gastric cancer precursors. Helicobacter 2019;24:e12548.CrossRef Da B, Jani N, Gupta N, Jayaram P, Kankotia R, Yao YuC, Dinis-Ribeiro M, Buxbaum J. High-risk symptoms do not predict gastric cancer precursors. Helicobacter 2019;24:e12548.CrossRef
15.
Zurück zum Zitat Nguyen TH, Tan MC, Liu Y, Rugge M, Thrift AP, El-Serag HB. Prevalence of gastric intestinal metaplasia in a multiethnic US veterans population. Clin Gastroenterol Hepatol 2020;14:S1542–3565(20)30325–6. Online ahead of print. Nguyen TH, Tan MC, Liu Y, Rugge M, Thrift AP, El-Serag HB. Prevalence of gastric intestinal metaplasia in a multiethnic US veterans population. Clin Gastroenterol Hepatol 2020;14:S1542–3565(20)30325–6. Online ahead of print.
16.
Zurück zum Zitat Oh S, Kim N, Yoon H, Choi YJ, Lee JY, Park KJ, Kim HJ, Kang KK, Oh DH, Seo AY, Lee JW, Shin CM, Park YS, Oh JC, Lee DH, Jung HC. Risk factors of atrophic gastritis and intestinal metaplasia in first-degree relatives of gastric cancer patients compared with age-sex matched controls. J Cancer Prev 2013;18:149–160.CrossRef Oh S, Kim N, Yoon H, Choi YJ, Lee JY, Park KJ, Kim HJ, Kang KK, Oh DH, Seo AY, Lee JW, Shin CM, Park YS, Oh JC, Lee DH, Jung HC. Risk factors of atrophic gastritis and intestinal metaplasia in first-degree relatives of gastric cancer patients compared with age-sex matched controls. J Cancer Prev 2013;18:149–160.CrossRef
18.
Zurück zum Zitat Fontham ET, Ruiz B, Perez A, Hunter F, Correa P. Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol 1995;90:1094–1101.PubMed Fontham ET, Ruiz B, Perez A, Hunter F, Correa P. Determinants of Helicobacter pylori infection and chronic gastritis. Am J Gastroenterol 1995;90:1094–1101.PubMed
19.
Zurück zum Zitat Fischbach LA, Graham DY, Kramer JR, Rugge M, Verstovsek G, Parente P, Alsarraj A, Fitzgerald S, Shaib Y, Abraham NS, Kolpachi A, Gupta S, Vela MF, Velez M, Cole R, Anand B, El Serag HB. Association between Helicobacter pylori and Barrett’s esophagus: a case-control study. Am J Gastroenterol 2014;109:357–368.CrossRef Fischbach LA, Graham DY, Kramer JR, Rugge M, Verstovsek G, Parente P, Alsarraj A, Fitzgerald S, Shaib Y, Abraham NS, Kolpachi A, Gupta S, Vela MF, Velez M, Cole R, Anand B, El Serag HB. Association between Helicobacter pylori and Barrett’s esophagus: a case-control study. Am J Gastroenterol 2014;109:357–368.CrossRef
20.
Zurück zum Zitat Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–1181.CrossRef Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–1181.CrossRef
21.
Zurück zum Zitat Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiol (Camb Mass) 2010;21:128–138.CrossRef Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiol (Camb Mass) 2010;21:128–138.CrossRef
22.
Zurück zum Zitat Zeeshan M, Salam B, Khalid QSB, Alam S, Sayani R. Diagnostic accuracy of digital mammography in the detection of breast cancer. Cureus 2018;10:e2448.PubMedPubMedCentral Zeeshan M, Salam B, Khalid QSB, Alam S, Sayani R. Diagnostic accuracy of digital mammography in the detection of breast cancer. Cureus 2018;10:e2448.PubMedPubMedCentral
23.
Zurück zum Zitat Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368:1980–1991.CrossRef Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, Gierada DS, Jones GC, Mahon I, Marcus PM, Sicks JD, Jain A, Baum S. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013;368:1980–1991.CrossRef
24.
Zurück zum Zitat Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB. Validation of the hepatocellular carcinoma early detection screening (HES) algorithm in a cohort of veterans with cirrhosis. Clin Gastroenterol Hepatol 2019;17:1886-1893.e5.CrossRef Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB. Validation of the hepatocellular carcinoma early detection screening (HES) algorithm in a cohort of veterans with cirrhosis. Clin Gastroenterol Hepatol 2019;17:1886-1893.e5.CrossRef
25.
Zurück zum Zitat Snir Y, Leibovitzh H, Leibovici-Weissman Y, Vilkin A, Cohen AD, Shochat T, Niv Y, Dotan I, Feldhamer I, Boltin D, Levi Z. Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients. U Eur Gastroenterol J 2021;9:343–353.CrossRef Snir Y, Leibovitzh H, Leibovici-Weissman Y, Vilkin A, Cohen AD, Shochat T, Niv Y, Dotan I, Feldhamer I, Boltin D, Levi Z. Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients. U Eur Gastroenterol J 2021;9:343–353.CrossRef
26.
Zurück zum Zitat Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018;67:28–35.CrossRef Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut 2018;67:28–35.CrossRef
27.
Zurück zum Zitat Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X, Tian SB, Yan C. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: A systematic review and meta-analysis. PLoS ONE 2015;10:e0142080.CrossRef Huang YK, Yu JC, Kang WM, Ma ZQ, Ye X, Tian SB, Yan C. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: A systematic review and meta-analysis. PLoS ONE 2015;10:e0142080.CrossRef
28.
Zurück zum Zitat Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141–147.CrossRef Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004;11:141–147.CrossRef
29.
Zurück zum Zitat Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Barbosa J, Guilherme M, Moreira-Dias L, Lomba-Viana H, Silva R, Abreu N, Lomba-Viana R. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia 2004;6:449–456.CrossRef Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Barbosa J, Guilherme M, Moreira-Dias L, Lomba-Viana H, Silva R, Abreu N, Lomba-Viana R. Validity of serum pepsinogen I/II ratio for the diagnosis of gastric epithelial dysplasia and intestinal metaplasia during the follow-up of patients at risk for intestinal-type gastric adenocarcinoma. Neoplasia 2004;6:449–456.CrossRef
30.
Zurück zum Zitat Agréus L, Storskrubb T, Aro P, Ronkainen J, Talley NJ, Sipponen P. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol 2009;44:564–570.CrossRef Agréus L, Storskrubb T, Aro P, Ronkainen J, Talley NJ, Sipponen P. Clinical use of proton-pump inhibitors but not H2-blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scand J Gastroenterol 2009;44:564–570.CrossRef
31.
Zurück zum Zitat Lorente S, Doiz O, Trinidad Serrano M, Castillo J, Lanas A. Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells. Gut 2002;50:13–18.CrossRef Lorente S, Doiz O, Trinidad Serrano M, Castillo J, Lanas A. Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells. Gut 2002;50:13–18.CrossRef
32.
Zurück zum Zitat Tan MC, Graham DY. Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020. Gastrointest Endosc 2019;90:457–460.CrossRef Tan MC, Graham DY. Gastric cancer risk stratification and surveillance after Helicobacter pylori eradication: 2020. Gastrointest Endosc 2019;90:457–460.CrossRef
Metadaten
Titel
Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population
verfasst von
Mimi C. Tan
Quynh Ho
Theresa H. Nguyen
Yan Liu
Hashem B. El-Serag
Aaron P. Thrift
Publikationsdatum
19.11.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 9/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07309-3

Weitere Artikel der Ausgabe 9/2022

Digestive Diseases and Sciences 9/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.